MUC16 and neoplasm: Importantly, CAR T cells have already been developed for both MUC16 (40) and MUC1 (45) including a tumor-specific glycoform, Tn-MUC1 (46), and therefore, further exploitation of these targets for treating advanced ovarian cancer is in order.